Mission Roll Call applauds Department of Veterans Affairs Secretary Doug Collins, Health and Human Services Secretary Robert F. Kennedy Jr., and the Advanced Research Projects Agency for Health (ARPA-H) for advancing research into ibogaine as a potential treatment for post-traumatic stress disorder (PTSD).

This initiative reflects what veterans have been telling Mission Roll Call: they want the federal government to explore promising new treatments, particularly for those who have not found relief through existing therapies.

In May 2026, Mission Roll Call surveyed 1,128 members of the veteran community about emerging PTSD and traumatic brain injury treatments. Seventy-five percent supported greater VA involvement in clinical trials involving treatments like ibogaine, while only 2% opposed it. Additionally, 76% supported medically supervised access to experimental treatments for veterans with treatment-resistant conditions.

Veterans also recognize the importance of scientific rigor. Ninety-six percent considered long-term tracking of treatment outcomes important, while 59% supported limiting ibogaine to controlled clinical settings, even if doing so delayed availability.

These findings demonstrate strong support for responsible innovation, grounded in scientific evidence and appropriate medical oversight.

Mission Roll Call commends VA and HHS for taking this important step toward evaluating additional treatment options for veterans. We look forward to research that establishes whether ibogaine can safely and effectively improve outcomes, and to ensuring that treatments demonstrating meaningful benefits become accessible and affordable to the veterans who need them.